Head-To-Head Analysis: Connect Biopharma (NASDAQ:CNTB) and BioAtla (NASDAQ:BCAB)

Connect Biopharma (NASDAQ:CNTB) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares Connect Biopharma and BioAtla’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	N/A	N/A
BioAtla	N/A	N/A	-289.67%

Valuation and Earnings

This table compares Connect Biopharma and BioAtla”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$2.95 million	17.97	-$74.94 million	($1.19)	-0.71
BioAtla	$8.50 million	0.39	-$59.61 million	($25.45)	-0.08

BioAtla has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Connect Biopharma and BioAtla, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1	0	8	0	2.78
BioAtla	1	0	1	0	2.00

Connect Biopharma presently has a consensus price target of $5.88, indicating a potential upside of 597.33%. BioAtla has a consensus price target of $200.00, indicating a potential upside of 9,850.25%. Given BioAtla’s higher possible upside, analysts clearly believe BioAtla is more favorable than Connect Biopharma.

Volatility and Risk

Connect Biopharma has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

About BioAtla

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.